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Abstract 
The evidence on the pathophysiology of the novel coronavirus SARS-CoV-2 infection is 
rapidly growing. Understanding why some patients suffering from COVID-19 are getting so 
sick, while others are not, has become an informal imperative for researchers and clinicians 
around the globe. The answer to this question would allow rationalizing the fear surrounding 
this pandemic. Understanding of the pathophysiology of COVID-19 relies on an 
understanding of interplaying mechanisms, including SARS-CoV-2 virulence, human 
immune response, and complex inflammatory reactions with coagulation playing a major role. 
An interplay with bacterial co-infections, as well as the vascular system and microcirculation 
affected throughout the body should also be examined. More importantly, a comprehensive 
understanding of pathological mechanisms of COVID-19 will increase the efficacy of therapy 
and decrease mortality. Herewith, presented is the current state of knowledge on COVID-19: 
beginning from the virus, its transmission, and mechanisms of entry into the human body, 
through the pathological effects on the cellular level, up to immunological reaction, systemic 
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and organ presentation. Last but not least, currently available and possible future therapeutic 
and diagnostic options are briefly commented on. 
Key words: COVID-19, SARS-CoV-2, epidemiology, immunology, acute respiratory 
distress syndrome, coagulation, therapy 
 
 
Introduction 
The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) and has rapidly spread around the globe, emerging as 
a significant threat worldwide [1]. Although evidence on the pathophysiology of COVID-19 
is rapidly growing, an understanding of the underlying pathological mechanisms which cause 
some patients to get seriously sick while others experience mild symptoms, remains hitherto 
unexplained. Understanding the underlying pathological mechanisms of the clinical features 
of the disease will increase the efficacy of management strategies and subsequently prevent 
many fatal outcomes.  
Herein  provided, is a comprehensive view of different pathological aspects of 
COVID-19, potentially influencing the vulnerable development of the disease. 
 
The SARS-CoV-2 virus, its transmission and entry points 
At the beginning of December 2019, a new respiratory tract disease was diagnosed 
among residents in the city of Wuhan, Hubei province, China [2, 3]. Yet unknown to that 
point, coronavirus (CoV), was referred to initially as 2019-nCoV, and was identified as the 
causative agent [2]. The viral genome sequencing revealed a ca. 80% sequence identity with 
the SARS-CoV virus, which caused the severe acute respiratory syndrome (SARS) outbreak 
in 2002 [3]. As a ribonucleic acid (RNA) virus it has a vast potential of mutating and 
generating sub-species or variants [4]. The SARS-CoV-2 virus was confirmed by reverse 
transcriptase-polymerase chain reaction (rRT-PCR) in sputum, saliva, nasal, pharyngeal and 
tracheal swabs, broncho-alveolar lavage, pleural effusion fluid, blood, feces, and occasionally 
in urine, and even semen [5–14]. According to World Health Organization (WHO), the 
detection of a single RNA sequence of coronavirus by rRT-PCR is uniform with the 
confirmation of the disease. To date, for instance, in Poland, two sequences are necessary 
[15]. 
The novel SARS-CoV-2 virus infection is mainly transmitted by micro-droplets 
generated in the airway of an infected person and is ejected during cough, sneeze and ordinary 
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talk [16, 17]. The droplets, containing viral load, can enter a host through the epithelial cells 
of the upper respiratory tract and conjunctiva [18]. The clinical and epidemiological 
importance of aerosol transmission remains under investigation [19]. However, the virus-
containing aerosol may reside for hours in the air in insufficiently ventilated rooms and 
spaces. So, overcrowded waiting rooms endanger patients through the exposition to increased 
initial viral load [16]. Some authors claim that transmission of the virus from bats to humans 
occurred through the digestive system, with gastrointestinal symptoms observed as the first or 
accompanying presentation of the disease with a varied frequency, from 1 to 36% of patients 
[14]. Additionally, as the virus can survive on a variety of surfaces for a surprising length of 
time, and its infective potential from this source remains unstudied [16]. If so, the 
transmission through ingestion cannot be ignored. However, the most difficult 
epidemiological challenge in COVID-19 is a period that lasts for several days of pre-
symptomatic replication and shedding of SARS-CoV-2 [20]. 
The virus uses a double-domain glycoprotein on its surface (S1), which has a high 
affinity to angiotensin-converting enzyme type 2 (ACE2) receptors, to invade cells [2, 3, 21]. 
Viral entry is enabled through the promotion of S1 by hosts transmembrane protease serine 2 
(TMPRSS2) and endosomal cysteine proteases cathepsin B and L [18, 22]. Expression of the 
ACE2 gene may differ between populations, thus explaining some geographical differences in 
COVID-19 severity [23]. Interestingly, a combination of inhibitors of both proteases blocked 
the virus entry in vivo effectively [22]. Given the vast representation of the receptors as 
mentioned above in human tissues, the virus itself has a broad capacity to infect various 
human cell types and induce different pathogenic chains of events that correspond with a 
variety of clinical pictures of COVID-19 [14, 24, 25]. Viral replication begins in the ciliated 
epithelium of the nasal cavity with the highest expression of its receptors in the 
goblet/secretory cells and the highest virus yield found in nasal swabs [18, 24]. Down the 
airway, the next target of the virus and the site of its replication with critical pathogenic 
implications is the lower respiratory tract and pneumocytes [7]. 
 
The virus versus the immune system 
Viral pathogenicity depends on its ability to overcome the host’s protective 
mechanisms of innate immunity. Innate immunity consists of natural barriers and nonspecific 
immune responses. The viral armor — its virulence — includes a variety of tricks. The host’s 
age and the virus adaptation add to the final seriousness of the disease in rats [26]. One 
missense mutation and a resulting single amino acid change in the S1 domain of the spike 
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protein, has increased its affinity to the ACE2 receptor. As a result, adult rats became 
susceptible and developed full picture of SARS, the young still not showing clinical signs 
[26]. This experiment is a warning for all of those who postulate isolation and social 
distancing only for the elder, more vulnerable members of the society. More so, as SARS-
Cov-2 differs from SARS with just a small sequence in the spike protein [27]. 
A molecular signature of any intruder in the respiratory system is checked on the 
surface of respiratory epithelium, interposed dendritic cells and tissue macrophages by means 
of toll-like receptors (TLRs), belonging to the superfamily of pattern recognition receptors 
(PRRs). The second control point is located inside the cells. MDA-5 and RIG-I receptors, 
which are present in the cytosol, sense, e.g., 5’triphosphate RNA or double-strand RNA — 
the specific by-products of viral replication. At the same time, host RNA is protected from 
recognition by a polypeptide cap on a 5’end. Upon recognition, interferons and other 
cytokines are secreted and are sent to the nucleus which signals to promote transcription of 
the proteins necessary to combat the intruder. The signaling relies upon biochemical reactions 
of phosphorylation and ubiquitination. Below, are mentioned some protective mechanisms 
that have been found in coronaviruses, as viral self-defense seems to be family specific. The 
strategies have been thoroughly described in an excellent review by Kikkert [28]. 
Viruses replicate in cytosol. Once there, they try to escape recognition through the 
enclosure of genetic material within capsules made of viral proteins and intracellular 
membranes (CoV proteins nsp3 and nsp4). Secondly, viral enzymes (e.g. CoV nsp16), are 
used to synthesize a cap which closely resembles the one, located at human RNA terminus 
and hiding its 5’end. It seems that during the infective cycle, the virus may auto divide its 
own RNA to avoid recognition. A viral protein has also been found, which packs the viral 
RNA to prevent destruction by the cellular machinery, programed to guard proper translation 
of the cellular own genetic material [28]. Apart from passive protection, viruses can actively 
switch-off host defense. Disruption of the transcription and translation inside the infected 
cells has been confirmed for SARS-CoV and MERS-CoV. Viruses interact with the formation 
of stress granules, containing untranslated mRNAs and serve as part of an antiviral response 
[29]. Ubiquitin-dependent regulatory processes in the cells, including activation of 
interferons, get disrupted upon viral infection due to the destruction of ubiquitin chains by 
viral proteases. Mechanisms which serve to avoid innate immunity are the virus license for 
survival and replication. Not surprisingly, SARS-CoV which utilizes almost all recognized 
methods, is so pathogenic. The innate immunity mechanisms weaken in advanced age, which 
adds to the vulnerability of the older population in the context of viral infections. 
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Why are elderly patients getting so sick? 
In fully competent subjects, dendritic cells and macrophages activated by cytokines, 
present viral antigens to the lymphocytes to recognize and destroy the virus. Anti-viral 
specific T cells, mainly CD8+ cytotoxic T cells, eliminate the infected cells. CD4+ T cells 
instruct B cells to produce specific antibodies that stop the spread of viral particles in body 
fluids. These mechanisms allow for containment of the infection within the lungs, viral 
clearance, and restitution of the damaged tissues. In patients with the burden of 
immunosenescence, the exaggerated inflammation does not induce a sufficient response of the 
lymphocytes, and the infection spreads further. The role of the immune system loses primary 
significance and non-immune factors related to necrosis of the tissues and decompensated 
circulation and ventilation become more important. However, persistent inflammation may 
still be responsible for opening entry gates for eventual bacterial infections and generalization 
of the changes into multiorgan failure and death [30]. This is probably the case of frail elderly 
but also younger subjects with similar deficiencies [31]. 
Aging of the immune system has common features present in all subjects, such as 
reduced production of T cells due to thymic atrophy, increased number of memory 
lymphocytes at the periphery and increased levels of serum proinflammatory cytokines [32]. 
Environmental factors can exaggerate these features into a level which is  a danger to 
survival. For example, so-called immune risk phenotype (IRP) is never seen in centenarians 
as its burden does not allow the elderly to fight effectively with infections, and they die earlier 
[33, 34]. Although many environmental factors affect the immune system, some of them 
notoriously deteriorate immunity (Table 1). These are mainly intracellular pathogens 
responsible for asymptomatic chronic infections such as the Herpesviridae family (with 
cytomegaly virus [CMV] in the first place) or Chlamydia sp. When infected with these 
pathogens, the subject cannot eradicate them but only control a possible progression of the 
infection. It is a lifelong game in which immunocompetent cells keep the pathogens dormant 
for as long as possible. Unfortunately, there is a price to pay for keeping the infections 
asymptomatic because long subclinical activation of the immune system creates its ‘attrition’ 
[35]. CD8+ T cells, the main cytotoxic subset responsible for clearance of the body from 
intracellular pathogens like viruses, proliferate and expand into big clones that occupy the 
immune space in the peripheral immune system. Unfortunately, these expanded clones, often 
marked as CD8+CD28– T cells, are anergic. They no longer respond to any pathogen and, at 
the same time, occupy immune space in the peripheral lymphoid system which hampers the 
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generation of immune responses mediated by naïve CD8 T cells and thus, influencing health 
status. For instance, it is an important cause for unresponsiveness to flu vaccines of the 
elderly [36]. Laboratory testing can be extremely precise here as was found herein, that the 
proper immune response occurs until the level of functional CD8+ T cells specific to CMV– 
phenotype CD8+CD28+antiCMV+ — is at least three cells per μL of peripheral blood [37]. 
Also, for this reason,  the popular expectation that an anti-SARS-CoV-2 vaccine will become 
a game-changer in the fight against the COVID-19 pandemic, may become a disappointment, 
particularly in the elderly. 
As clinical symptoms in COVID-19 suggest an uncontrolled immune response, a 
deeper insight into the features of immunosenescence may help to understand the 
pathogenesis of COVID-19 and reveal immune biomarkers identifying those at highest risk of 
fatal complications. Importantly, immunosenescence does not affect only the elderly. The 
immune system of younger subjects affected by the burden of chronic diseases undergoes 
similar changes very often. The theory presented above can serve as one of the possible 
explanations of the fact that young patients can also suffer fatality from COVID-19 [38]. 
Immunosenescence also affects CD4+ T cells. A reduced number of these cells is 
responsible for severe immunodeficiencies, as in human immunodeficiency virus (HIV) 
infection. Together with a high proportion of CD4+CD28– T cells this can be observed in the 
elderly and is associated with anergy of the immune system.[31] The changes within this 
subset are less related to chronic infections and correlate rather with the presence of chronic 
non-communicable diseases with some inflammatory background, such as rheumatoid 
diseases, diabetes, atherosclerosis, and neurodegeneration [34]. Immunosenescence and 
inflammation within the lymphoid compartment are counteracted by an increased level of 
anti-inflammatory CD4+FoxP3+ T regulatory cells, which accumulate with age. 
Nevertheless, they are only effective in some subjects as in the majority of the elderly, the 
function of T regulatory cells is impaired, and even the higher numbers do not compensate for 
this impairment [39]. Altogether, decreased CD4/CD8 ratio with confirmed CD28– 
expansions and reduced absolute number of CD4+ T cells is an important feature of IRP, 
which can be used to identify those at high risk of COVID-19 [40]. Indeed, a recent report on 
the immune phenotype in 60 patients from Wuhan confirmed the majority of this 
characteristic as predictive factors. Patients who developed severe COVID-19 were 
characterized by lymphopenia and significantly reduced numbers of both CD4+ and CD8+ T 
cells in peripheral blood. Importantly, the recovery was associated with an increasing number 
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of CD8+ T cells during the therapy. In contrast, the level of those cells in non-responders to 
the therapy did not change or even decreased [40]. 
 
The COVID-19 lung pathology 
Initially, the COVID-19 disease begins with symptoms of mild respiratory tract 
infection — fever, cough, and fatigue [41]. While most commonly COVID-19 patients 
present with relatively mild viral pneumonia, some of them, for a reason not completely 
understood, progress to acute respiratory distress syndrome (ARDS) with profound hypoxia 
[42]. Indeed, SARS-CoV (the one responsible for previous SARS epidemic) particles ORF8b 
and viroporin 3a induce endoplasmic reticulum stress, lysosomal damage, and cell death of 
pneumocytes and robustly activate NLRP3 inflammasome — the innate system of pathogen 
recognition in macrophages [43]. The inflammasome formation results in the secretion of 
proinflammatory cytokines [44]. Unfortunately, viral particles switch on the apoptosis of 
macrophages, too. The consequences of this recognition depend on the immune background 
of the patient. If the patient is affected by an IRP and inflammaging, the secretion of 
proinflammatory cytokines may quickly increase beyond the regulated levels, and the process 
of ARDS is launched [32]. The accumulation of anergic lymphocytes that express memory 
phenotype is a big source of proinflammatory cytokines, like interleukin 1 (IL1), IL6, tumor 
necrosis factor alpha. 
The cytokine storm, which is observed between 7th to 10th day in some fulminant 
COVID-19 cases is likely explained through antibody-dependent enhancement of the 
inflammatory reaction, well described in Dengue infection [45–47]. Formation of immune 
complexes containing SARS-CoV-2 and non-neutralizing antibodies leads to a life-
threatening inflammatory response [45, 46]. These complexes, by binding to the Fc receptor 
for immunoglobulin, enable SARS-CoV-2 to enter and replicate in new, non-pneumocyte, 
target cells: antigen-presenting dendritic cells and macrophages. Interestingly, the time 
relationship between the formation of the first antibodies and the dramatic acceleration of the 
initially mild inflammatory lung destruction can be noticed around the 7th–10th day of 
symptomatic COVID-19 [47]. Interestingly, on average 5% of convalescents have completely 
undetectable antibodies against SARS-CoV-2, suggesting that perhaps rapid — other than 
humoral — immune responses might be crucial for viral clearance and recovery [48]. 
Indeed, increased levels of these cytokines belong to the strong predictors of frailty in 
the elderly, and this feature of immunosenescence is often called inflammageing [49, 50]. 
Lymphocytes probably prime the ignition of inflammageing. Other potent producers of 
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proinflammatory cytokines include innate immune cells, such as monocytes and 
macrophages, and non-immune cells, such as adipocytes. The latter, together with adipose-
lymphoid tissue crosstalk, obesity, and diabetes are beyond the scope of the present 
discussion. Nevertheless, as an extremely important source of inflammation, they should not 
be forgotten [51]. Healthy aging tends to limit the inflammation with increasing levels of anti-
inflammatory CD14+CD16+ M2 monocytes/macrophages, which spread throughout the 
tissues [52]. On the other side, classical CD14++CD16– M1 monocytes/macrophages 
accumulate preferentially within damaged tissues such as arterial walls with atherotic plaques 
where they escape the regulation by M2 cells and CD4+FoxP3+ T regulatory cells. M1 cells 
excrete proinflammatory factors and the phenotype itself is significantly linked with 
atherosclerotic/inflammatory/diabetes age-associated diseases [53, 54]. For these reasons, 
increased levels of activated monocytes, notably M1 phenotype, and high levels of 
proinflammatory cytokines, mainly notorious IL6, are also important features of IRP. 
Moreover, inherited higher IL6 levels in serum were reported and associated with a higher 
risk of atherosclerosis and complications after hematopoietic stem cell transplantation [55, 
56]. High level of proinflammatory cytokines from different sources in frail elderly people 
narrows the margin where their effects are only local and can be accommodated by 
mechanisms of the body homeostasis. Hence, a sudden increase in their level provoked by 
systemic stimuli, like a generalized viral disease, bacteremia, massive inflammation on the 
mucosal surface (pneumonia) or sepsis, may easily escape the regulation and trigger systemic 
responses within the definition of ‘cytokine storm’, systemic inflammatory response 
syndrome (SIRS) or ARDS [57]. 
The cytokines increase the permeability of endothelium and increase the adhesion of 
immune cells to vessel walls through the expression of selectins and integrins induced on the 
endothelial surface, while NO and prostacyclin also produced by activated macrophages 
trigger relaxation of media smooth muscles and vasodilatation [58]. The fluid leaking through 
the vessel walls accumulate in the pulmonary parenchyma but also leak through damaged 
pneumocytes to the pulmonary alveoli. Mucous secretion is stimulated and soon the alveoli 
and bronchial tree are flooded. Dying macrophages, pneumocytes and the endothelium are 
abundant sources of tissue factor. Thus, the extrinsic pathway of coagulation is activated in 
plasma throughout the pulmonary vasculature, resulting in the clinical picture of local 
coagulation [59]. Obstruction of pulmonary capillaries by thrombi and local inflammatory 
vasodilation contributes to veno-arterial shunt and profound hypoxia observed in the severe 
COVID-19 patients [15, 42, 59, 60]. The process is limited by the immune status of the 
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patient as the mechanisms described above accelerate into vicious positive feedback loops. 
The role of downregulating the anti-inflammatory effect of ACE2 receptors by SARS-CoV-2 
was recently described in an excellent review by Huang et al. [61]. For example, macrophages 
are activated by thrombin and further activate coagulation, or activated endothelium attracts 
immune cells and immune cells adhered to its surface further increases the activation of 
endothelial cells.  
 
Coagulation and thrombosis in COVID-19 
Initial reports from China, reported patients suffering from a severe or fatal COVID-
19 disease course, with slightly lower platelet count and a higher level of d-dimer [41, 62]. 
But it was the first reports from Italy and other European countries, which emphasized the 
remarkably high incidence of pulmonary embolism and thrombosis in the most severe and 
fatal cases [59, 60, 63]. At present, there is an awareness of a few clinical and laboratory 
features of patients with COVID-19, which is thrombocytopenia, elevated d-dimer level, 
prothrombin time prolongation and disseminated intravascular coagulation [64, 65]. The 
International Society of Thrombosis and Hemostasis (ISTH) recommends prothrombin time, 
platelet, fibrinogen and d-dimer to determine prognosis and identify patients requiring 
admission to hospital [65]. The rise of d-dimer, seen in the majority of patients with 
confirmed COVID-19, may be due to the fibrinolytic processes and subsequent spillover into 
the bloodstream [66, 67]. The hypercoagulable state can be explained by systemic 
inflammatory response alone, resulting in both massive activation of coagulative pathways, 
and at the same time, inhibition of fibrinolysis, which may be caused by up-regulation of 
PAI1 gene [64]. Coagulation disorders are correlated with the severity of bacterial and viral 
infections [68]. But they can be triggered through systemic or local inflammation involving 
the endothelium, platelets, and plasma factors [69, 70]. Also, in COVID-19 endothelial 
dysfunction, high von Willebrand factor activity, and probably genetic factors play an 
essential role in the process. Age and diabetes have been reported risk factors of a fatal 
outcome from COVID-19, but they are also well-known risk factors for deep venous 
thrombosis [41, 71, 72]. Moreover, there are confirmed genetic determinants of deep venous 
thrombosis, including inherited protein C, S, von Willebrand factor, and antithrombin 
deficiencies, specific single nucleotide polymorphisms, and haplotypes [73–79]. The role of 
inherited thrombophilic disorders in the risk of severe COVID-19 has not as yet been 
emphasized or investigated to date. 
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Klok et al. [60] reviewed 184 patients with COVID-19 admitted to an intensive care 
unit (ICU), of whom 31% experienced thrombotic events — particularly pulmonary embolism 
[80]. Surprisingly, the majority of infected individuals remained resistant to high doses of 
both low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) [60]. 
Although it was speculated that it might result from a decreased antithrombin level, it appears 
that the failure to achieve therapeutic prolongation of activated partial thromboplastin time 
results from abnormally high levels of factor VIII [81]. Bleeding disorders reported in 
COVID-19 patients are surprisingly rare — approximately 2% of cases — and present mostly 
with mild petechiae due to depletion of platelet [82]. However, the common coagulopathy in 
severe COVID-19 seems to be local pulmonary thrombosis, a vast portion of ICU patients 
develop a systemic disseminated intravascular coagulation (71.4% of non-survivors vs. 0.6% 
of survivors), though it may still be a systemic picture of massive local endothelial injury 
during ARDS development [62, 83, 84]. Nevertheless, the first reports are available, which 
document the beneficial effect of heparin use on the outcome from COVID-19 [83]. The 
present report considers that to achieve proper anticoagulation, agents that target either 
thrombin directly or factor Xa may be regarded as an alternative if high-dose LMWH or UFH 
appears ineffective. Also of note, less interest has been paid, so far, to antiplatelet therapy in 
COVID-19, with acetylsalicylic acid in front of it. Also, tissue plasminogen activator was 
already considered as an eventual adjunct therapy in severe COVID-19 patients with severe 
ARDS [85]. 
Interestingly, there have been reports of transient anticardiolipin IgA, anti-B2-
glycoprotein IgA, and IgG antibodies presence (commonly associated with antiphospholipid 
syndrome) in three COVID-19 positive patients admitted to ICU. All of them developed 
complex coagulopathy and ARDS, with evidence of ischemia in physical examination. One of 
them experienced multiple cerebral infarcts [86]. Therefore, it is also hypothesized that the 
occurrence of nonspecific neurologic symptoms reported in some COVID-19 patients may be 
explained through disseminated intravascular coagulation and micro-emboli in the brain [62, 
87, 88]. 
 
COVID-19 as a systemic disease — the clinical staging 
COVID-19 has been classified as an acute respiratory infection with a possibility of 
progression to respiratory insufficiency, multiorgan failure, and ultimately death. Mortality in 
COVID-19 increases steeply in the elderly being notoriously high in those 80 years old and 
older [41, 89, 90]. It has been universally accepted to stage the seriousness of COVID-19, 
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according to Modified Early Warning Score (MEWS), based on clinical parameters: 
frequency of breath, pulse rate, systolic arterial pressure, hourly diuresis, body temperature 
and the state of consciousness [91]. Points from 1 to 3 are attributed to the positive or 
negative deviation of each parameter from the baseline and summated, giving the total score. 
Hospitalization is required for each patient presenting with dyspnea and/or radiologic signs of 
pneumonia (stage 2 and above). MEWS equal to and above three and/or SpO2 90–92% are 
symptomatic for severe pneumonia (stage 3), the patient needs continuous monitoring of vital 
parameters and the risk of the organ failure is increased. Patients in the fourth stage of the 
disease suffer at least from acute respiratory distress syndrome with paO2/FiO2 ratio below 
300 mmHg and require respiratory support within the intensive therapy facilities [15, 92]. 
 
Acute kidney injury in COVID-19 
Up to 30% of patients with COVID-19 admitted to an ICU presented with symptoms 
of acute kidney injury (AKI), advanced to stage 3, according to the 2012 Kidney Disease: 
Improving Global Outcomes (KDIGO) [93, 94]. Wang et al. [12] denies AKI being caused 
directly by the SARS-CoV-2 virus. However, renal podocytes and proximal tubule cells 
express both of the viral receptors — ACE2 and TMPRSS2, serving as a target for it [12, 23]. 
Virus particles were identified in podocytes and proximal tubular epithelium on autopsy [95]. 
Prominent acute proximal tubule injury was observed, which manifested itself as the loss of 
brush border, vacuolar degeneration, dilatation of the tubular lumen with cellular debris, and 
occasionally even frank necrosis and detachment of epithelium with the bared tubular 
basement membrane [95]. Glomerular thrombosis, fibrin sediments or platelet aggregates 
were not observed, suggesting that local thrombosis had not been triggered [95]. Intensivists 
from the United Kingdom suggested a careful water balance assessment in patients with 
COVID-19 ARDS on admission to ICU,  apart from the heavy lung injury, they frequently 
presented with dehydration and even hypovolemia. Combined with “keep the lung dry” rule 
for ARDS therapy, this led to increased AKI prevalence.  
 
COVID-19 in the cardiovascular system 
Although cardiovascular comorbidities seem to be a key threat in patients with 
COVID-19, thus far, the underlying mechanisms remain unknown. Preceding coronavirus 
outbreaks essentially involved the cardiovascular system by causing complications, i.e. 
hypotension, arrhythmias, myocarditis, etc. [96, 97]. COVID-19 infection seems to have 
comparable cardiac manifestations. The infection with SARS-CoV2 is associated with cardiac 
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dysfunction as well as arrhythmias and the nature of the myocardial injury appears to be 
serious in the COVID-19 subset (Fig. 1) [98] 
First and foremost, several groups reported that many patients with COVID-19 were 
diagnosed as having an acute myocardial injury, manifested mainly by elevated levels of 
high-sensitive troponin. For instance, an increase in high-sensitivity cardiac troponin I levels 
(>28 pg/mL) occurred in 5 of the first 41 patients diagnosed with COVID-19 in Wuhan, 4 of 
them were admitted to ICU [99]. Shi et al. [100] reported 57 fatal outcomes of which 10.6% 
had coronary artery disease, 4.1% had heart failure, and 5.3% had cerebrovascular disease. 
Similarly, Guo et al. [98] reported that myocardial injury is significantly associated with fatal 
outcome of COVID-19. 
Non-coronary, direct myocardial injury via upregulation of ACE2 proteins is most 
likely the cause. SARS-CoV-2 enter cells to trigger infection by using ACE2 protein/receptor, 
facilitating virus entry into lung alveolar epithelial cells. Of note, ACE2 is also highly 
expressed in the human heart, vascular cells, pericytes, kidneys and gastrointestinal tract 
[101–103]. Thus, it is almost certain that acute cardiovascular complications are not 
secondary to lung disease. Although it is hypothesized that the treatment strategy based on the 
usage of renin–angiotensin–system (RAS) inhibitors, i.e., angiotensin-converting enzyme 
inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may promote SARS-CoV-2 
binding to ACE2, there is no clear evidence supporting up-regulation processes of ACE2 in 
human tissues [104, 105]. Notably, in preclinical studies, ARBs appeared to have a potentially 
protective effect [106]. SARS-CoV-2 may also enter cells through the CD209 receptor, 
expressed in macrophages, and promoting virus invasion into immune cells in cardiac and 
vascular tissues [107]. 
Alternative mechanisms of myocardial injury comprise the cytokine storm, hypoxia-
induced excessive intracellular calcium leading to cardiac myocyte apoptosis [104, 108, 109]. 
Cardiac injury activates the innate immune response and releases proinflammatory cytokines. 
Since autopsy revealed interstitial mononuclear inflammatory infiltrates in the heart tissue, 
inflammation could be one of the potential mechanisms of acute myocarditis, ischemia and 
heart failure in the COVID-19 setting [110]. In these cases, arrhythmias might be associated 
with infection-related myocarditis which appears several days after the initiation of fever 
[111]. The virus-mediated lysis of cardiomyocytes is usually followed by a T-cell response 
and further myocardial injury and heart failure [112]. 
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Since endothelial cell involvement has been recognized across different vascular beds, 
endothelial dysfunction may substantially contribute to the pathomechanism of COVID-19. 
Of note, ACE2 receptors were also found on the endothelial cells and, in the in vitro study, 
SARS-CoV-2 directly infected human blood vessel organoids [113]. Injured endothelium, 
with histological signs of inflammatory infiltration, evidence of endothelial and inflammatory 
cell death, were present in different human organs including heart, the small intestine, lung, 
kidney, and liver [114]. In 1 case, myocardial infarction was reported with no sign of 
lymphocytic myocarditis [114]. Endothelial dysfunction might be caused by direct infection 
and an inflammatory response, finally leading to microvascular dysfunction, organ ischemia, 
inflammation and subsequently to apoptosis [114, 115]. In summary, endothelial dysfunction, 
cytokine storm, oxidative stress, as well as upregulation of angiotensin-II may essentially 
explain the coagulopathy seen in severe COVID-19 patients [116]. Last but not least, since 
hypercoagulability and systemic inflammatory activity can persist, COVID-19 infection may 
influence long-term outcomes [117]. Although, to date, no long-term outcome measure  is 
known, a history of SARS-coronavirus infection is associated with cardiovascular 
comorbidities, including, for instance, glucose metabolism disorders [97]. Inflammatory 
mechanisms and activation of immune responses underlie a broad range of cardiovascular 
diseases including atherosclerosis, heart failure or hypertension [55, 118]. Importantly, 
generalized endothelitis and subsequent microcirculatory dysfunction, which is observed in 
many local vascular beds in COVID-19 patients, and might be an interesting target for 
treatment strategies, especially in high-risk vulnerable patients. 
 
Therapeutic options 
COVID-19 is an infectious disease, which has direct pharmacological implications. 
According to the basic knowledge, its natural history can be divided into four stages — early 
infection, pulmonary phase, hyperinflammation, and recovery (Fig. 2) [47]. Before a definite 
solution for COVID-19 treatment is found, the efforts of the scientific community are dual. 
The first path is directed against the SARS-CoV-2 virus itself. There is a need to determine 
which of the antiviral agents that have already been synthesized and tested through the first 
and second phase of approval, which prove sufficiently effective to block the virus entry 
and/or stop or slow down its multiplication to gain time for the innate and adapted reaction of 
the whole immune system. Within this approach, a list of agents have already been tested, 
including the combination of chloroquine or hydroxychloroquine with azithromycin, 
oseltamivir, lopinavir/ritonavir, darunavir, favipiravir, remdesivir and ivermectin. [15, 119–
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122]. With different, either unspecific or targeted mechanisms of action, each of them had 
been successfully used against other viruses or parasites. However, up to the date of 
completion of this manuscript, only chloroquine in Poland and remdesivir in the USA, have 
gained recommendation as the first-line treatment against COVID-19 [15, 123]. 
It is obvious that the success of direct antiviral treatment relies upon its application 
during the phase of viral entry and replication. The main fault of many clinical trials of 
antiviral agents lies in the fact that the treatment, for a variety of reasons, begins too late. First 
symptoms and/or signs of pneumonia, which often trigger the inclusion of the patient into a 
clinical trial can appear as late as 15 to 20 days after infection [47]. It should not be 
overlooked that such an approach, although safer from an insurance point of view, can leave 
us without appropriate and targeted treatment for many years on. For example, chloroquine 
has already been proven to reduce the viral load in vitro and early observations on its 
usefulness in vivo have been enthusiastic [122]. Later on, contrary results appeared in France 
[120]. Moreover, the arrhythmogenic properties have resulted in numerous interactions which 
make its safety questionable [120]. Currently, results of clinical trials of chloroquine are 
eagerly awaited, 23 of which are registered in China. Also, when it comes to WHO 
recommendations of chloroquine, ethical, and political considerations come into view. As it is 
the basic antimalarial drug, worldwide shortages could easily occur, rendering the huge and 
vulnerable population devoid of a cheap and easy cure [122]. Among direct antiviral agents, 
remdesivir seems to be the most promising one at the moment. Other options are still 
emerging, as screening for their possible targets and drug compositions is currently enhanced 
by high output computational analysis, modeling, and artificial intelligence tools [124]. 
Unfortunately, in the meantime too many victims of the viral attack get too seriously 
ill. So, in parallel, alternative paths of effective supportive treatment for all those patients 
must be created, and in whom the virus has successfully evaded the forces of their immunity. 
It would be an inappropriate waste of time if we did not take advantage of the accumulated 
knowledge on the pathogenesis of a variety of viral diseases, observe, make analogies, and 
draw conclusions. COVID-19 is not an entirely new disease. The closest relatives are SARS 
and MERS, and the stages of the disease resemble already known syndromes [27, 47]. 
Nonetheless, a timely prediction of the subsequent events and appropriate choices and timing 
of the intervention still pose the main challenges of supportive treatment. Curbing or 
modifying the inflammation phase requires a detailed understanding of the processes that take 
place down to the molecular signal levels. Antiviral therapies often prove ineffective in late 
phases of viral diseases, as they are more loosely linked to the viral presence. The phenomena 
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which are observed in the advanced stages of COVID-19 are rather due to the insufficient, 
over-induced, or dysregulated response of the immune system and its counterparts in the 
human body, the most important of them being the coagulation system. If the damage of the 
infected cells, caused by the pathogen, is profound enough, even elimination of the virus may 
not protect people against the consequences of the primary infection. At this point, it is worth 
remembering that in COVID-19, as well as with other viral diseases, the response of the body 
depends on the viral load [125]. 
The supportive treatment can be initiated as early as the appearance of the first 
symptoms of the disease and perhaps even earlier, once the infected person tests positive. 
Hospital physicians may easily neglect the prehospital, but in the natural course of viral 
diseases, it may play an important role. Which interventions can be based on the 
pathophysiology of viral infections and receive attention and recommendations from primary 
care physicians? Can early, prehospital prone positioning prevent respiratory deterioration? 
Vitamins (C, D3) and microelements (zinc, selenium) are key coenzymes and active centers 
of multiple enzymes within the immune system. Their anti-inflammatory and antioxidant 
properties play an important role in overall health. Is there enough evidence supporting 
additional supplementation? Which of the medicines available over the counter can be 
recommended and are there any that should be avoided? 
Overwhelming dyspnea and rapid deterioration have become the most threatening 
symptoms of COVID-19, often promoting early hospitalization in fear of being overlooked. In 
the descriptions of the clinical picture of pulmonary involvement, a long-lasting period of 
progressive desaturation without overt dyspnea is often mentioned as a prodromal phase to 
fulminant respiratory insufficiency [42]. A question remains, whether a population-wide use 
of pulse oximetry, under the guidance of family physicians and/or with the aid of telehealth 
applications, provides an easy answer to this problem. Such an approach would possibly 
decrease the risk of contracting the infection or supplementary viral load during the 
consultation at the outpatient and/or inpatient department and provide timely help when 
necessary. Patients and staff protection from the unnecessary use of scarce hospital resources 
would also limit the overall burden of the disease. 
The knowledge on the immunosenescence and IRP is probably most useful in the 
assessment of patients at risk of fatal COVID-19. Timely recognition of the cytokine storm at 
the beginning of a systemic response to the virus through increased IL6 measurements, 
increases the probability of successful immunomodulatory treatment with anti-IL6 
(tocilizumab) or general suppression with high dose corticosteroids or maneuvers to wash out 
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cytokines, i.e., with hemofiltration [15, 126]. Moreover, identification through genotyping of 
the vulnerable population — i.e., carriers of the IL6 proinflammatory mutations or deep 
venous thrombosis risk haplotypes, may be used for more patient-tailored therapies. 
Nevertheless, one should remember that high levels of IL6 last for several hours only, and 
then SIRS changes into compensatory anti-inflammatory response syndrome with prevalent 
suppressive cytokines, like IL10 [32]. That being said, the suppression with antibodies against 
pro-inflammatory cytokines or glucocorticoids during the late phase might only deepen the 
problems. Hemofiltration is still a very unspecific method and may also devoid the body of 
many small regulatory molecules, either anti-inflammatory or those necessary for 
homeostasis. As it has been described in the previous section, the cytokine crisis leads to 
excessive activation of the coagulation cascade, which must be appropriately addressed in 
therapy. Due to the lack of robust data, LMWH is still recommended, though it remains based 
on single, small group studies [62]. 
The summary of supportive intensive therapy treatment (oxygen therapy, methods of 
ventilation, extracorporeal membrane oxygenation, etc.) in patients with severe disease have 
recently been summarized and will not be repeated here [15, 127]. 
A special place among the currently approved treatments belongs to the application of 
convalescent plasma [15, 128, 129]. Its potential is mixed and not yet definitely studied. The 
first possibility involves direct neutralization of the virus by the donor antibodies. The second 
includes immunoregulatory mechanisms. The plasma from COVID-19 survivors might be 
then very useful in immobilizing the virus but also attenuating antibody-dependent 
enhancement, similarly to intravenous immunoglobulin G, which can potentially harness 
SIRS. The natural process of switching from the inflammatory to the resolution phase is the 
most difficult to study and understand. Clinically it is recognized by the fall of the body 
temperature, return of consciousness, normalization of vascular tone, and regaining of 
physical strength.  
The question remains what happens at the cellular, biochemical, and molecular levels 
and how to support the body to limit its answer to recognition and elimination of the 
pathogen. The process has been extensively studied during the last ten years and many of the 
biochemical signals involved have been identified [130]. The synthesis of specialized pro-
resolving mediators requires substrates, biochemical energy and triggering [131]. The 
substrates are derived from the essential fatty acids — eicosapentaenoic acid and 
docosahexaenoic acid. The mediators are clustered in families named resolvins, protectins, 
and maresins. Subfamilies are then attributed cardinal letters and numbers, e.g., resolvin D3 
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(RvD3). The molecules have been found in the human white blood cells as well as in a variety 
of tissues late in the inflammation phase. The concentration of resolvins in tissues increases 
along with the decrease of the levels of pro-inflammatory prostaglandins and leukotrienes. 
The process occurs physiologically, initiated along with the inflammatory cascade of 
prostaglandins and leukotrienes, but can also be triggered by external substances. One of the 
substances that can move the balance towards resolution of the inflammation is a well-known 
acetylsalicylic acid — aspirin, and one of the induced resolvins is AT-RvD3 (aspirin-
triggered resolvin D3). AT-RvD3 successfully limited inflammation in experimental models 
(murine peritonitis) and blocked transmigration of human leucocytes across epithelial cells. 
RvD3 has been shown to appear late in the resolution phase, promoting macrophages that 
clean apoptotic cells. The transition towards the anti-inflammatory phase is also confirmed by 
the reversal of concentrations of interleukins — increased IL10 and decreased IL6 [130]. In 
aging mice, decreased concentration of pro-resolving lipid derivatives has been linked to 
prolonged duration of an acute inflammatory state [132]. 
The above-mentioned acetylsalicylic acid, or aspirin, is one of the most ancient 
treatment options which demands closer attention. For a long time holding the first place in a 
basic set of drugs prescribed during most pyretic diseases of childhood, aspirin was dethroned 
by paracetamol when attributed to the potential of induction of the Rey disease. The 
recognition of its anticoagulant properties resulting from the interplay with platelet receptors 
has led to a triumphant comeback. Nowadays aspirin is the must-of-cardioprotection and the 
strongest holding preventive measure against most of the complications of atherosclerosis. 
However, the protective role of aspirin is not limited to its anti-aggregatory properties, as 
aspirin is one of the recognized triggers of resolvin synthesis [132]. It has been found that 
many of these specialized pro-resolving mediators play an important role in limiting 
inflammation in chronic airway diseases. SMPs take part in changing the activity of 
neutrophils and macrophages, regulate the function of different subsets of lymphocytes, 
including the promotion of B-cell differentiation and aid in the restriction of cytokine 
production. Protectin D1 has been shown to improve survival in a mouse model of lethal viral 
respiratory infection [133]. The lipid phase of the fluid accumulating in the alveoli during the 
resolution phase of ARDS contains a high concentration of docosahexaenoic acid-derived 
resolvin D3. It has been experimentally shown, that aspirin triggered resolvin D3 (AT-RvD3) 
can promote the resolution of inflammation in the pulmonary epithelium in the course of 
acute lung injury [131]. Could COVID-19 patients benefit from replacing immunosuppression 
with aspirin? From the experimental and observational data, it seems possible that aspirin, 
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through the induction of RvD3, can prevent the inflammatory hyperreaction known as the 
cytokine storm. Is it not high time to seriously reconsider the protective role of aspirin in the 
infective respiratory diseases of adulthood? 
At the moment, in the absence of a vaccine or targeted therapy, the only available 
preventive methods are non-specific (testing and isolation, quarantine, protection of porta of 
entry, sanitary cordon, social distancing, etc.) — as if we have been moved back in time. 
Understanding even the tiniest details of the pathogenesis of viral infections, like interactions 
between viral proteins and receptors on human target cells, the broad complexity of the 
immune responses and the functioning of the labyrinth of the coagulation system — have 
profound practical consequences: scientific, clinical, epidemiological, and economic. If these 
pathogenetic puzzles had been arranged another way — the general scenario of this pandemic 
could have been completely different.  Viral genomes can quite easily be manipulated, but 
desperately lacking is an understanding of how such changes can affect our lives in a broader 
perspective. 
COVID-19 outbreak has dramatically exposed our weaknesses on the individual, 
scientific, and organizational levels. However, it has also given us a chance to rethink and 
test, how strong we are when our efforts unite. One of the first symptoms is a fact in which 
we can conclude this lesson, and that is an unprecedented global open access to high-quality 
knowledge and international exchange of clinical experience, organizational and technical 
know-how. 
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Table 1. Risk factors of the immune risk phenotype. 
Immune factors 
Expanded clones of CD8+ T cells (CD8+CD28–), CD8 T oligoclonality 
Reduced percentage and number of CD4+ T cells 
Decreased CD4/CD8 index 
Inflammageing — high level of proinflammatory cytokines, like interleukin 6 
Monocytosis with M1 monocytes 
Cytomegaly virus positivity 
Clinical factors 
Atherosclerosis-related diseases 
Inflammatory/autoimmune chronic diseases including late-onset asthma, chronic obstructive 
pulmonary disease, and pulmonary fibrosis 
Diabetes and obesity 
Neurodegeneration 
History of non-responsiveness to vaccination (for example: flu) 
 
 
 
Figure 1. Mechanisms of cardiovascular failure in COVID-19. 
 
 
Figure 2. Phases and severity grading of COVID-19 — after Siddiqi [47], modified. During 
early infection virus replication and shedding is rapidly accelerating within the first 4–10 days 
(Phase I). Together with the cytopathic effect of the virus replication clinical symptoms occur 
and the first immunological mechanisms are triggered (Phase II). With an occurrence of the 
first non-neutralizing antibodies, antibody-dependent augmentation of inflammation occurs, 
which together with local thrombosis and sepsis leads to multiple organ failure (MODS), 
acute respiratory distress syndrome (ARDS), acute kidney injury (AKI) and deep venous 
thrombosis (DVT) and pulmonary embolism (PE). COVID-19 may present with four stages 
of severity, either as a mild respiratory tract infection, viral pneumonia, severe pneumonia, or 
ARDS. 


